Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Thorac Oncol. 2011 Jun;6(6):1059-65. doi: 10.1097/JTO.0b013e318215a4dc.

A smoking cessation intervention for thoracic surgery and oncology clinics: a pilot trial.

Author information

  • 1Mongan Institute for Health Policy, Harvard Medical School, Boston, Massachusetts, USA. epark@partners.org

Erratum in

  • J Thorac Oncol. 2011 Aug;6(8):1454.

Abstract

INTRODUCTION:

Although most smokers diagnosed with lung cancer report that they want to quit smoking, many do not succeed. Smokers who quit when lung cancer is diagnosed have improved treatment efficacy, quality of life, and survival. Effective smoking cessation interventions targeted to thoracic oncology patients are needed.

METHODS:

This pilot study examined the feasibility and potential efficacy of a 12-week program that combined smoking cessation counseling with varenicline. Seven-day point prevalence tobacco abstinence rates at the end of treatment were compared with a usual care control group. From January 2008 to August 2009, patients with a diagnosed or suspected thoracic malignancy were recruited at their initial visit to a thoracic surgeon or thoracic oncologist at Massachusetts General Hospital.

RESULTS:

Of 1130 patients screened, 187 (17%) were current smokers, and an additional 66 (6%) reported quitting within the past 6 months. One hundred sixteen (67%) of smokers were eligible, and 49 (42%) of eligible smokers enrolled (control group n = 17, intervention group n = 32). Intervention participants completed a median of nine counseling sessions; 50% of intervention participants completed the full varenicline course. At 12-week follow-up, biochemically validated 7-day point prevalence tobacco abstinence rates were 34.4% in the intervention group versus 14.3% in the control group (odds ratio = 3.14, 95% confidence interval = 0.59-16.62, p = 0.18).

CONCLUSION:

Our findings support the feasibility and acceptability of this program. At the end of treatment, quit rates were higher in the intervention [corrected] group. Further testing is indicated to establish the efficacy of this treatment package in a randomized clinical trial.

PMID:
21512406
[PubMed - indexed for MEDLINE]
PMCID:
PMC3104083
Free PMC Article

Images from this publication.See all images (2)Free text

Figure 1
Figure 2
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins Icon for PubMed Central
    Loading ...
    Write to the Help Desk